Research Index entry · Trial
The Ozempic pill didn’t slow early Alzheimer’s in two big trials
- Evidence
- People · two final-stage trials
- Source
- doi.org
- Added
- 19 November 2026
What it is
Semaglutide is the drug inside Ozempic, one of the GLP-1 drugs used for diabetes and weight. In two final-stage trials, evoke and evoke+, 3,808 people aged 55 to 85 with early Alzheimer’s and confirmed amyloid took a daily semaglutide pill or a placebo for two years. Memory, thinking and daily life declined at the same pace in both groups, even though a blood marker of inflammation fell. The trials raised no new safety worries.
Where it stands
- Lab discovery
- Animal studies
- First studies in people
- Large trials
- Approved
A clear no for slowing early Alzheimer’s. Whether GLP-1 drugs help prevent dementia before symptoms start wasn’t tested.
Update timeline
What changed
Newest first. Only changes to the subject itself appear here: new information, or something proven wrong.
- WatchingThe Scouts look again every Friday
Only new information or a correction shows up here, not another mention of the same thing.
- Update
Research connections
Why these belong together
A connection has to say what it adds. Shared keywords alone don’t count.
Trial · Trial registry
AR1001 missed its main goal in its final-stage trialAnother pill tested in a final-stage Alzheimer’s trial in 2026, with a mixed result.
People · final-stage trial · company data